Search Results 231-240 of 15170 for TNF

  1. Publications - Michael C. Stephens, M.D. - Mayo Clinic

    2023 Jun 23; 21(1):410. View PubMed; Reinhart JP, Aird JL, Stephens MC, Asch S, Orandi AB, Tollefson MM. Tumor necrosis factor-alpha inhibitor-induced ...

  2. A Study to Evaluate the Effectiveness and Safety of Glepaglutide in the Treatment of Short Bowel Syndrome - Mayo Clinic

    Unstable biological therapy (e.g., anti-TNF-α, natalizumab, etc.) within 6 months prior to Screening, including significant changes in doses or switch of ...

  3. Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer - Mayo Clinic

    ... tumor necrosis factor [anti-TNF] agents) ≤ 2 weeks prior to registration. Note: Patients who have received acute, low dose, systemic immunosuppressant ...

  4. CardiolRx In Recurrent Pericarditis Following IL-1 Blocker Cessation - Mayo Clinic

    Canakinumab, TNF inhibitors, IL-6 inhibitors, or janus-activating kinase inhibitors (within 12 weeks) 4. Intravenous immune globulin (IVIG) (within 8 weeks)

  5. https://www.mayoclinic.org/chinese_patient_consumer_faq.xml

  6. https://www.mayoclinic.org/spanish_patient_consumer_faq.xml

  7. https://www.mayoclinic.org/spanish_procedure_concepts.xml

  9. https://www.mayoclinic.org/arabic_procedure_concepts.xml

  10. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Mayo Clinic

    Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g. ...